Anti-Viral Program
Viral Infections
Pre-clinicalActive
Key Facts
About MicroQuin
MicroQuin is a private, preclinical-stage biotech developing first-in-class therapeutics that target the IntraCellular Environment (ICE) to treat cancer, viral infections, and neurodegeneration. Its core hypothesis is that disease progression is driven by destabilization of the cellular interior, and its drugs aim to restore balance by modulating specific ICE regulators. The company has garnered non-dilutive funding from government grants and established a key collaboration with Eli Lilly's TuneLab, positioning its lead oncology program for potential IND-enabling studies. MicroQuin represents a high-risk, high-reward venture targeting fundamental biological mechanisms across multiple major therapeutic areas.
View full company profileTherapeutic Areas
Other Viral Infections Drugs
| Drug | Company | Phase |
|---|---|---|
| Haptenized Viral Vaccines | BioVaxys | Preclinical |
| Cell-based Antiviral Drug Discovery Platform | Lucerna | Development |
| XAV19 | Xenothera | Preclinical |
| Antiviral Screening Services | NeoVirTech | Pre-clinical |
| Satiasolv | Marinomed Biotech | Pre-clinical |
| Telomir-1 | Telomir Pharmaceuticals | Pre-clinical |
| DehydraTECH for Antivirals | Lexaria Bioscience | Preclinical |
| RECCE® 529 | Recce Pharmaceuticals | Preclinical |